Adocia Has More Votes Than Shares — and Its Vote Count Grew in a Month It Issued Nothing

Adocia, the French biotech that trades in the U.S. as the ADR ticker ADOCY, closed out August with 20,253,056 shares outstanding. It also reported 21,413,132 voting rights. In an American filing that sentence would be a typo. In France it is a legitimate bookkeeping fact: some of those shares simply vote twice.

The disclosure is a monthly ritual required by French securities law (Article L.233-8 of the Commercial Code and Article 223-16 of the AMF's general regulation). Every listed French company must report its share count and its voting rights. It sounds like the dullest footnote in the capital-structure universe, but Adocia's version is quietly doing two jobs at once. It is the running ledger of how the company pays its bills — and of who gets to decide that the bills get paid again.

The report is really three numbers, and the gaps between them are the story.

Number one is the share count: 20,253,056. Number two is "theoretical voting rights": 21,413,132. Number three is "exercisable voting rights": 21,361,494.

Why would a company have more theoretical votes than shares? Double voting rights — the French device under which shares held in registered form (in your own name rather than a broker's) for at least two years carry two votes instead of one. It is a loyalty reward that pays out in control: the longer and more directly you hold, the more your ballot weighs, no matter how many shares the company prints on top of you.

The gap between the second and third numbers is different. Theoretical voting rights count every share, even ones whose votes are suspended; exercisable voting rights exclude the shares Adocia holds in its own treasury under a liquidity agreement. Right now that difference is about 51,600 shares — the pile the company holds so it doesn't obviously swing its own meetings.

Then comes the part that makes the August filing worth a few minutes. Adocia issued zero new shares in August — the share count is exactly what it was at the end of July — yet its voting rights still went up. Theoretical votes rose from 21,411,232 to 21,413,132, and exercisable votes from 21,357,282 to 21,361,494. Nobody bought anything; the tally drifted upward on its own, mostly because more registered shares crossed the two-year mark and picked up their second vote, and because the treasury position shrank a touch. Votes are not a fixed multiple of shares. They compound quietly toward the patient.

You should care because the share side of this ledger is not frozen for long. Adocia is a clinical-stage diabetes-and-obesity biotech that burns cash — €9.7 million in the bank at June 30 — and it is financing its pipeline the way French micro-caps often do: with an "avance en compte courant," a shareholder current-account advance. In April 2026 it signed one with Vester Finance, its biggest institutional shareholder: up to €6 million over 24 months, repayable either in cash (interest accrues at 7% if you repay that way) or in newly issued shares — up to 1.5 million of them, just under 7.6% of the company — at a small discount to the market price. The stated point is to stretch the runway into early Q2 2027.

Repaying a loan by printing shares is issuing equity to your lender. In July, that is exactly what happened: 200,000 new shares went to Vester. Every time that happens, the share count climbs and everyone else's slice shrinks.

But double voting rights bend that dilution math in a direction most U.S. investors won't expect. The freshly issued shares to Vester start with one vote each — the two-year clock begins on day one — while the founders' aged registered shares keep their extra weight. The disclosure around the Vester deal makes the lopsidedness explicit: if the shares are fully issued, Vester would own about 11% of the capital but cast about 10.3% of the votes, while the Soula co-founders would own about 5% of the capital but cast about 8.6% of the votes. Your money buys votes faster than it buys shares; theirs buys shares faster than votes. The entity supplying the cash gets pulled toward one-share-one-vote, and the people who have been there longest get amplified.

That is the machine the monthly filing reports on. In most months the ledger shows dilution (share count up) or accretion (votes up) or both. The August report shows a rare month where neither the company nor the bank moved a share — and the vote count drifted up regardless. For a micro-cap living on shareholder loans, that sticky, slightly lopsided control structure is worth more than the share count alone suggests: the people who hold the extra votes are the people deciding whether the next loan becomes equity on top of you, too.